The Firmicutes/Bacteroidetes ratio of the human gut microbiota is associated with prostate enlargement

The pathophysiology of the prostate enlargement underlying lower urinary tract symptoms is unknown. Meanwhile, the gut microbiota can contribute to various host conditions. We hypothesized that the gut microbiota plays a role in prostate enlargement.

[1]  S. Yachida,et al.  The gut microbiota associated with high‐Gleason prostate cancer , 2021, Cancer Science.

[2]  G. Netto,et al.  Gut Microbiota–Derived Short-Chain Fatty Acids Promote Prostate Cancer Growth via IGF1 Signaling , 2021, Cancer Research.

[3]  David A. Drew,et al.  Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals , 2021, Nature Medicine.

[4]  B. Strukelj,et al.  The Influence of Probiotics on the Firmicutes/Bacteroidetes Ratio in the Treatment of Obesity and Inflammatory Bowel disease , 2020, Microorganisms.

[5]  N. Nonomura,et al.  Influence of Diet and Nutrition on Prostate Cancer , 2020, International journal of molecular sciences.

[6]  Y. Taur,et al.  Gut uropathogen abundance is a risk factor for development of bacteriuria and urinary tract infection , 2019, Nature Communications.

[7]  A. Wolfe,et al.  Implications of the Genitourinary Microbiota in Prostatic Disease , 2019, Current Urology Reports.

[8]  D. Ankerst,et al.  Metabolic Biosynthesis Pathways Identified from Fecal Microbiome Associated with Prostate Cancer. , 2018, European urology.

[9]  K. McVary,et al.  A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis , 2018, The Prostate.

[10]  L. McCullough,et al.  Age‐related changes in the gut microbiota influence systemic inflammation and stroke outcome , 2018, Annals of neurology.

[11]  M. Carini,et al.  Benign prostatic enlargement can be influenced by metabolic profile: results of a multicenter prospective study , 2017, BMC Urology.

[12]  E. Hsiao,et al.  Interactions between the microbiota, immune and nervous systems in health and disease , 2017, Nature Neuroscience.

[13]  F. Bäckhed,et al.  Signals from the gut microbiota to distant organs in physiology and disease , 2016, Nature Medicine.

[14]  C. Eng,et al.  The Urinary Microbiome Differs Significantly Between Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Controls as Well as Between Patients With Different Clinical Phenotypes. , 2016, Urology.

[15]  Masahira Hattori,et al.  The gut microbiome of healthy Japanese and its microbial and functional uniqueness , 2016, DNA research : an international journal for rapid publication of reports on genes and genomes.

[16]  James Kinross,et al.  The gut microbiota and host health: a new clinical frontier , 2015, Gut.

[17]  M. Lucia,et al.  Prostate Biopsy Markers of Inflammation are Associated with Risk of Clinical Progression of Benign Prostatic Hyperplasia: Findings from the MTOPS Study. , 2015, The Journal of urology.

[18]  U. Das,et al.  Urinary microbiota in patients with prostate cancer and benign prostatic hyperplasia , 2015, Archives of medical science : AMS.

[19]  R. Kirby,et al.  Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) – focus on the UK , 2015, BJU international.

[20]  Michael J. Zilliox,et al.  The Female Urinary Microbiome: a Comparison of Women with and without Urgency Urinary Incontinence , 2014, mBio.

[21]  Michael J. Zilliox,et al.  Urine Is Not Sterile: Use of Enhanced Urine Culture Techniques To Detect Resident Bacterial Flora in the Adult Female Bladder , 2013, Journal of Clinical Microbiology.

[22]  Edward Giovannucci,et al.  The correlation between metabolic syndrome and prostatic diseases. , 2012, European urology.

[23]  W. Isaacs,et al.  Monocyte chemotactic protein‐1 (MCP‐1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia , 2010, The Prostate.

[24]  P. Turnbaugh,et al.  Microbial ecology: Human gut microbes associated with obesity , 2006, Nature.

[25]  J. S. St. Sauver,et al.  Tracking of longitudinal changes in measures of benign prostatic hyperplasia in a population based cohort. , 2006, The Journal of urology.

[26]  E. Purdom,et al.  Diversity of the Human Intestinal Microbial Flora , 2005, Science.

[27]  D. Bostwick,et al.  Prostatic central zone volume, lower urinary tract symptom severity and peak urinary flow rates in community dwelling men. , 1999, The Journal of urology.

[28]  Yi Wu,et al.  The Prostate , 2020 .

[29]  A. Partin,et al.  Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer , 2018, The Journal of urology.

[30]  C. Roehrborn,et al.  The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. , 2010, European urology.